Alx Oncology Holdings Inc Stock
Alx Oncology Holdings Inc Stock price
Key metrics
| Market capitalization | $98.50m |
| Enterprise Value | $-40.75m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 0.30 |
| P/B ratio (TTM) P/B ratio | 0.62 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-180.59m |
| Free Cash Flow (TTM) Free Cash Flow | $-134.41m |
| Cash position | $156.72m |
Is Alx Oncology Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
Alx Oncology Holdings Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Alx Oncology Holdings Inc forecast:
Analyst Opinions
7 Analysts have issued a Alx Oncology Holdings Inc forecast:
Financial data from Alx Oncology Holdings Inc
| Jun '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.85 -0.85 |
54%
54%
|
|
| EBITDA | -180 -180 |
32%
32%
|
EBIT (Operating Income) EBIT | -181 -181 |
31%
31%
|
| Net Profit | -171 -171 |
32%
32%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Alx Oncology Holdings Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Alx Oncology Holdings Inc Stock News
Company Profile
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia on April 1, 2020 and is headquartered in Burlingame, CA.
| Head office | United States |
| CEO | Jason Lettmann |
| Employees | 72 |
| Founded | 2015 |
| Website | www.alxoncology.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
